Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

Item
http://www.wikidata.org/entity/Q37410279
Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatmentChoi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.Targeted therapies in renal cell cancer: recent developments in imagingPET imaging of early response to the tyrosine kinase inhibitor ZD4190.Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs.Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.Cervical cancer cell-derived angiopoietins promote tumor progression.Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.Advances in studies of tyrosine kinase inhibitors and their acquired resistance.Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study.
P2860

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

Item
http://www.wikidata.org/entity/Q37410279
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@en
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@nl
type
label
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@en
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@nl
prefLabel
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@en
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@nl
P1433
P1476
P2093
P304
P31
P356
P478
P577
P698
P356
P1433
P1476
Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.
@en
P2093
P304
P31
P356
P478
P577
P698